Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
SG&A Expense Growth
2.64%
Quarterly · Period ending:
LCTX SG&A Expense Growth
Latest reported2.64%period ending
Latest reported2.64%period ending
LCTX Quarterly SG&A Growth (QoQ) (0.00% → 2.64%)
Latest values, visible window
High-resolution chart · PNG
LCTX sg&a expense growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | SG&A Expense Growth |
|---|---|
| 2.6357% | |
| 4.7815% | |
| 15.7719% | |
| -8.0921% | |
| -6.1149% | |
| 10.3613% | |
| -0.2041% | |
| 1.0772% | |
| -9.9298% | |
| 16.8637% | |
| 2.5736% | |
| -4.8953% | |
| -10.055% | |
| 8.6477% | |
| -1.6735% | |
| -16.0911% | |
| -37.7731% | |
| 91.4331% | |
| -16.7952% | |
| 17.2178% | |
| 15.2732% | |
| 11.917% | |
| -3.0871% | |
| -7.1648% | |
| -13.5207% | |
| 0.333% | |
| -2.2782% | |
| -26.3503% | |
| -27.7367% | |
| 23.1338% | |
| 9.5142% | |
| 22.8621% | |
| -13.5175% | |
| 4.0096% | |
| 26.6841% | |
| 3.7079% | |
| -13.2915% | |
| -4.5293% | |
| 16.8124% | |
| -31.0729% | |
| -44.1038% | |
| 16.1303% | |
| 35.4937% | |
| 21.969% | |
| 19.4485% | |
| 8.0741% | |
| 12.4476% | |
| -11.8802% | |
| 31.872% | |
| -14.4129% | |
| 0.3948% | |
| 17.846% | |
| 6.0134% | |
| 2.6721% | |
| 48.876% | |
| -7.4052% | |
| 1.8971% | |
| -20.0872% | |
| 53.6039% | |
| -21.2768% | |
| 22.8796% | |
| 18.8092% | |
| 14.6387% | |
| -6.5134% | |
| 67.8644% | |
| 145.6633% | |
| -177.5035% | |
| 192.9673% | |
| 31.9526% | |
| -20.6494% | |
| 8.5056% | |
| 48.8295% | |
| 22.1175% | |
| 16.9512% | |
| 72.2176% | |
| -26.3228% | |
| -29.6826% | |
| 18.5807% | |
| 16.6906% | |
| -24.9653% | |
| -7.8973% | |
| 20.0199% | |
| 49.8045% | |
| -27.4528% | |
| -26.2251% | |
| 5.8438% | |
| 52.8022% | |
| -23.3727% | |
| -10.2984% | |
| 28.8526% | |
| 39.3581% | |
| -39.9229% | |
| 12.079% | |
| -37.9877% | |
| 259.6523% | |
| -47.8899% | |
| -12.3051% | |
| 82.3513% | |
| -75.2405% | |
| 19.6473% |